OncoMatch/Clinical Trials/NCT06391892

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Is NCT06391892 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for pancreatic cancer.

Phase 3RecruitingElisabethinen HospitalNCT06391892Data as of May 2026

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify